Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
PLoS One ; 11(6): e0155822, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27299728

RESUMO

BACKGROUND AND AIMS: MELD allocation system has changed the clinical consequences on waiting list (WL) for LT, but its impact on mortality has been seldom studied. We aimed to assess the ability of MELD and other prognostic scores to predict mortality after LT. METHODS: 301 consecutive patients enlisted for LT were included, and prioritized within WL by using the MELD-score according to: hepatic insufficiency (HI), refractory ascites (RA) and hepatocellular carcinoma (HCC). The analysis was performed to predict early mortality after LT (8 weeks). RESULTS: Patients were enlisted as HI (44.9%), RA (19.3%) and HCC (35.9%). The major aetiologies of liver disease were HCV (45.5%). Ninety-four patients (31.3%) were excluded from WL, with no differences among the three groups (p = 0.23). The remaining 207 patients (68.7%) underwent LT, being HI the most frequent indication (42.5%). HI patients had the shortest length within WL (113.6 days vs 215.8 and 308.9 respectively; p<0.001), but the highest early post-LT mortality rates (18.2% vs 6.8% and 6.7% respectively; p<0.001). The independent predictors of early post-LT mortality in the HI group were higher bilirubin (OR = 1.08; p = 0.038), increased iMELD (OR = 1.06; p = 0.046) and non-alcoholic cirrhosis (OR = 4.13; p = 0.017). Among the prognostic scores the iMELD had the best predictive accuracy (AUC = 0.66), which was strengthened in non-alcoholic cirrhosis (AUC = 0.77). CONCLUSION: Patients enlisted due to HI had the highest early post-LT mortality rates despite of the shortest length within WL. The iMELD had the best accuracy to predict early post-LT mortality in patients with HI, and thus it may benefit the WL management.


Assuntos
Transplante de Fígado/mortalidade , Listas de Espera , Adulto , Idoso , Ascite/mortalidade , Ascite/terapia , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/terapia , Feminino , Insuficiência Hepática/mortalidade , Insuficiência Hepática/terapia , Humanos , Cirrose Hepática/mortalidade , Cirrose Hepática/terapia , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/terapia , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Obtenção de Tecidos e Órgãos/organização & administração
3.
Transplant Rev (Orlando) ; 25(3): 91-101, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21530219

RESUMO

The substantial immigration into Spain from endemic areas of Chagas disease such as Latin America has increased the number of potential donors of organs and tissues. In addition, an increasing number of patients with advanced Chagas heart disease may eventually be eligible to receive a heart transplant, a universally accepted therapeutic strategy for the advanced stages of this disease. Therefore, it is necessary to establish protocols for disease management. This document is intended to establish the guidelines to be followed when a potential donor or a tissue or organ recipient is potentially affected by Chagas disease and summarizes the action criteria against the possibility of Chagas disease transmission through the donation of organs, tissues, or hematopoietic stem cells and aims to help professionals working in this field. A single registry of transplants in Trypanosoma cruzi infected donors and/or recipients will provide and disseminate experience in this area, which has shown a low recorded incidence to date.


Assuntos
Doença de Chagas/cirurgia , Doença de Chagas/transmissão , Transplante de Coração , Transplante de Células-Tronco Hematopoéticas , Doadores de Tecidos , Doença de Chagas/prevenção & controle , Humanos , Sistema de Registros
4.
Rev Esp Enferm Dig ; 103(4): 191-5, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21526872

RESUMO

BACKGROUND: in recent years many factors have been shown to influence dose received by the patient during ERCP. Therefore it is necessary to update radio induced cancer risk. OBJECTIVES: to calculate lifetime attributable risk of cancer during ERCP. To compare the risk with the most common X-ray examinations. DESIGN: descriptive study with 393 consecutive ERCP performed at one center. Equipment used was Philips BV pulsera. In each exploration demographic and anthropometric variables of the patient were collected. Dosimetric quantities were calculated from exposure parameters. Effective dose was estimated using specific conversion factors. Organ doses and radio induced cancer incidence was estimated. RESULTS: dose area product was 0.82 mGym2(IQR 0.4-1.5) with an average fluoroscopy time of 2 minutes and 45 seconds. Entrance surface dose was 30.7 mGy (IQR 15-60.8) and effective dose was 0.44 mSv (IQR 0.2-0.9). Multivariate analysis identified that difficult papillary cannulation (ß 0.4; p = 0.009), patient age (ß-0.01; p = 0.001) and therapeutic applied (ß= 0.89; p < 0.001) influenced dose-area product. The ERCP dose would be equivalent to the radiation received by twenty chest radiographs and would be about fourteen times smaller than a barium enema or twenty times less than that received during an abdominal CT. Life-time attributable risk of cancer incidence was 4.08 and 16.81 per million procedures in diagnostic and therapeutic ERCP respectively. CONCLUSIONS: from the radiological point of view, ERCP is a safe technique that uses low exposure levels compared to other explorations commonly used in medicine. It implies a reasonably low risk of radio induced cancer.


Assuntos
Colangiopancreatografia Retrógrada Endoscópica/efeitos adversos , Neoplasias Induzidas por Radiação/etiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Relação Dose-Resposta à Radiação , Feminino , Fluoroscopia/efeitos adversos , Humanos , Incidência , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Neoplasias Induzidas por Radiação/epidemiologia , Órgãos em Risco/efeitos da radiação , Dosagem Radioterapêutica , Risco
6.
Gastroenterol Hepatol ; 30(1): 22-4, 2007 Jan.
Artigo em Espanhol | MEDLINE | ID: mdl-17266878

RESUMO

Gastrointestinal stromal tumors (GIST) are an infrequent cause (<1%) of severe gastrointestinal hemorrhage. Treatment is mainly surgical through complete tumoral resection. We report the case of a 29-year-old woman who presented to the emergency room with severe gastrointestinal bleeding manifested by melena. On physical examination the patient had a painless, palpable mass in the left abdomen. Esophagogastroduodenoscopy, computed tomography, angiography and urgent surgical intervention led to diagnosis of a jejunal GIST.


Assuntos
Hemorragia Gastrointestinal/etiologia , Tumores do Estroma Gastrointestinal/complicações , Neoplasias do Jejuno/complicações , Adulto , Feminino , Humanos , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA